ITGA2 and ITGAV surface expression is affected by DNM activity in human MKs. (A-B) Quantification of ITGAV (part of a receptor to FN) at the surface of CHRF cells. Flow cytometry representative histograms and quantification in 4 experiments measuring ITGAV at the surface of CHRF cells. ITGAV staining shows a decrease in surface expression in CHRF with DNM2 and DNM3 knockdown when compared with control (CTRL; by 22%; paired Student t test P < .05). (C-D) Quantification of ITGAV at the surface of MKs. Flow cytometry representative histograms and quantification in 4 experiments measuring ITGAV at the surface of MKs. (E-F) ITGAV staining also showed a consistent slight decrease in primary MKs treated with DNSR (by 10%) when compared with control (paired Student t test P < .05). Quantification of ITGA2 at the surface of MKs. Flow cytometry representative histograms and quantification in 4 experiments measuring ITGA2 at the surface of MKs. ITGA2 staining (part of a receptor to collagen) showed a decrease in surface expression in primary MKs treated with DNSR (by 26% when compared with CTRL; paired Student t test P < .05). Error bars indicate standard errors of the mean of ≥3 independent experiments. *P ≤ .05, **P ≤ .01.